Completed PHASE3 INTERVENTIONAL 2-arm NCT04880980

Comparison of Efficacy of Double Dose Oral Terbinafine Vs Itraconazole in Treatment of Dermatophyte Infections of Skin.

Comparison of Efficacy of Double Dose Oral Terbinafine Versus Itraconazole in Treatment of Dermatophyte Infections of Skin - A Prospective, Randomized Controlled Trial

Sponsor: Pak Emirates Military Hospital

Conditions Dermatophyte Infection Itraconazole Adverse Reaction Terbinafine Adverse Reaction

Interventions Itraconazole capsule Terbinafine Pill

Updated 5 times since 2021 Last updated: Mar 19, 2022 Started: Mar 15, 2021 Primary completion: Mar 15, 2022 Completion: Mar 15, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Dermatophyte Infection and Itraconazole Adverse Reaction, this trial is completed. The trial is conducted by Pak Emirates Military Hospital and has accumulated 5 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2022 — Jul 2024 [monthly]

Completed PHASE3
Apr 2022 — May 2022 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Jun 2021 — Apr 2022 [monthly]

Recruiting PHASE3

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pak Emirates Military Hospital

Data source: Pak Emirates Military Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rawalpindi, Pakistan